Study proves safety and effectiveness of novel radionuclide therapy for neuroendocrine neoplasms

Reviewed by Emily Henderson, B.Sc.Nov 23 2021

A new type of peptide receptor radionuclide therapy (PRRT) has been shown to control disease in 85 percent of patients with metastatic neuroendocrine neoplasms, achieving complete remission in some patients. The first-in-human study utilized ¹⁷⁷Lu-DOTA-LM3 therapy, which was administered without severe adverse effects and was well tolerated by the majority of patients. This research was published in the November issue of The Journal of Nuclear Medicine.

Neuroendocrine neoplasms are tumors that arise from diffuse neuroendocrine system cells. They are most commonly found in the gastrointestinal tract, pancreas and lungs. Neuroendocrine neoplasms are fairly rare diseases, but their incidence and prevalence have increased substantially in recent decades. The majority of neuroendocrine tumors overexpress somatostatin receptors (SSTRs), which are targeted for imaging and treatment.

Over the past two decades, SSTR-targeted imaging using radiolabeled somatostatin agonists followed by PRRT has been remarkably successful in managing neuroendocrine tumors. However, potent SSTR antagonists-;which only poorly internalize into tumor cells if at all-;have surprisingly been shown to be even superior to agonists for such purposes."

Jingjing Zhang, MD, PhD, Assistant Professor, Department of Diagnostic Radiology at the Yong Loo Lin School of Medicine, National University of Singapore in Singapore

To further investigate the role antagonists can play in treating neuroendocrine tumors researchers developed a study to determine the safety, biodistribution and efficiency of a new type of SSTR antagonist, ¹⁷⁷Lu-DOTA-LM3. Fifty-one patients with progressive, heavily pretreated neuroendocrine neoplasms underwent PRRT with ¹⁷⁷Lu-DOTA-LM3. Treatment-related adverse events were graded for all participants, and dosimetry was performed for 11 patients.

¹⁷⁷Lu-DOTA-LM3 was administered without severe adverse effects and was well tolerated by most patients. Disease control was reached in 40 out of 47 patients (85 percent) who were monitored after ¹⁷⁷Lu-DOTA-LM3 therapy. Two patients achieved complete remission by the European Organization for Research and Treatment of Cancer criteria.

Of note, the uptake and dosimetry of the antagonist ¹⁷⁷Lu-DOTA-LM3 were compared with those of the commonly used SSTR agonist ¹⁷⁷Lu-DOTATOC in patients undergoing treatment on the same dosimetry protocol. ¹⁷⁷Lu-DOTA-LM3 demonstrated higher uptake and a longer effective half-life in tumor lesions, resulting in higher tumor radiation doses than for agonist ¹⁷⁷Lu-DOTATOC.

"These encouraging findings demonstrate the feasibility and superiority of SSTR antagonist ¹⁷⁷Lu-DOTA-LM3 as compared to SSTR agonists. Furthermore, antagonist PRRT can be performed under concurrent treatment with somatostatin analogues without the need for interrupting these medications. This is especially important for patients suffering from carcinoid syndrome or even carcinoid crisis," stated Richard P. Baum, MD, PhD, president of the academy at the International Centers for Precision Oncology (ICPO) and consultant for the Center for Advanced Radiomolecular Precision Oncology, CURANOSTICUM Wiesbaden-Frankfurt, both in Germany. "The results are very encouraging for theranostic applications of SSTR antagonists to further improve outcomes in patients with neuroendocrine neoplasms in the future."

This study was made available online in March 2021.